Background: The study will attempt to evaluate the safety and effectiveness of intracervical misoprostol in comparison with intravaginal and sublingual for the induction of labor at term. Methods: three hundred term pregnancies requiring induction of labor were treated with 50μg of misoprostol intracervical, sublingual and vaginal. Participants were randomly allocated into three groups of 100. The dose was repeated every 4 hours until adequate uterine contraction and Bishop score were achieved. The duration of induction to delivery, time to active phase, the rate of delivery, and the need for cesarean section were compared in three groups. Additionally, labor course and side effects were recorded and analyzed.Results: Labor was successfully induced in all cases, most (63%) of which required a single dose of misoprostol. Ninety-three (93.0%) cervical patients proceeded to spontaneous vaginal delivery, also this figure was the same in the vaginal and sublingual group 83 (83.0%), The other 41 cases received cesarean delivery with more indications failure to progress and meconium-stained liquor. The results showed that 278 (92.7%) deliveries were achieved in less than 10 hours. Time from start of medication to the active phase of labor and delivery were 3.01 ± 0.86 and 6.1 ± 1.3 hours in the Cervical group, 4.2 ± 0.66 and 8.4 ± 0.92 hours in the sublingual group, and 5.06 ± 1.1 and 9.2 ± 1.5 hours in the vaginal group respectively (p<0.001). Cesarean rate was lower in the cervical group than the two other groups (p=0.05). No significant differences were observed between the study groups in terms of Apgar score and meconium-stained amniotic fluid. Moreover, no maternal and neonatal complication were seen.Conclusion: In addition to the sublingual and intravaginal routes of administration, intracervical misoprostol at a single dose of 50μg appears to be an effective method for induction of labor in women with an unfavorable cervix. Similar to all medical interventions, a discussion of the risks, benefits, and alternatives to induction of labor with this medication in each individual woman should be undertaken prior to treatment. Trial registration: This clinical study was approved by the Iranian Registry of Clinical Trials (http://www.irct.ir) with the IRCT ID: IRCT20190415043278N1, Registration and approval date was 2019-05-13 and 2019-05-27 respectively.